ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R ...
Ascletis submits two IND applications to the US FDA to treat obesity: ASC36 once-monthly injection & ASC36_35 FDC once-monthly injection: Hong Kong Tuesday, July 7, 2026, 12:00 Hr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results